HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (4- fluorophenyl)- N'- phenyl- N'- (pyrimidin- 2- ylmethyl)- 1,3,5- triazine- 2,4,6- triamine

an inhibitor of KCNH3 voltage-gated potassium channels

Also Known As:

ASP2905

Networked: 2 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - N-(4-fluorophenyl)-N'-phenyl-N'-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine: 2
  - Triazines: 306
    - N-(4-fluorophenyl)-N'-phenyl-N'-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine: 2

Experts

1.	Ni, Keni: 2 articles (01/2020 - 01/2018)
2.	Takahashi, Shinji: 2 articles (01/2020 - 01/2018)
3.	Okamura, Ai: 1 article (01/2020)
4.	Yamazaki, Mayako: 1 article (01/2020)
5.	Honda, Sokichi: 1 article (01/2018)
6.	Ohmiya, Makoto: 1 article (01/2018)

Related Diseases

1.	Cognitive Dysfunction 01/01/2020 - "These findings suggest that ASP2905 potentially mitigates cognitive impairments caused by schizophrenia, such as attention deficits. " 01/01/2020 - "Therefore, ASP2905 may alleviate the broad spectrum of symptoms of schizophrenia, including positive and negative symptoms and cognitive impairments, which is in contrast to currently available antipsychotics, which are generally only partially effective for ameliorating these symptoms."
2.	Schizophrenia (Dementia Praecox) 01/01/2020 - "These findings suggest that ASP2905 potentially mitigates symptoms of schizophrenia, such as apathy. " 01/01/2020 - "These findings suggest that ASP2905 potentially mitigates cognitive impairments caused by schizophrenia, such as attention deficits. " 01/01/2020 - "Therefore, ASP2905 may alleviate the broad spectrum of symptoms of schizophrenia, including positive and negative symptoms and cognitive impairments, which is in contrast to currently available antipsychotics, which are generally only partially effective for ameliorating these symptoms."
3.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/01/2018 - "The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder." 01/01/2018 - "ASP2905 (0.1 and 0.3 mg/kg, po) significantly prolonged cumulative latency as effectively as methylphenidate (0.1 and 0.3 mg/kg, sc), which is the gold standard for treating ADHD. " 01/01/2018 - "Together, these findings suggest that ASP2905, which acts through a novel mechanism, is as effective for treating ADHD as currently available drugs such as methylphenidate." 01/01/2018 - "Further, ASP2905, amphetamine, and methylphenidate significantly increased the alpha-band power of rats, suggesting that ASP2905 increases arousal, which is a pharmacologically important activity for treating ADHD. "
4.	Stroke (Strokes) 01/01/2018 - "We used a multiple-trial passive avoidance task to investigate the effects of ASP2905 on inattention and impulsivity in juvenile stroke-prone spontaneously hypertensive rats. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Methylphenidate (Ritalin)
3.	Amphetamine (Amfetamine)